Johnson & Johnson (NYSE:JNJ) Shares Purchased by J. W. Coons Advisors LLC

Posted by Defense World Staff on May 11th, 2023

J. W. Coons Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,212 shares of the company’s stock after purchasing an additional 739 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of J. W. Coons Advisors LLC’s investment portfolio, making the stock its 7th biggest holding. J. W. Coons Advisors LLC’s holdings in Johnson & Johnson were worth $5,337,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in JNJ. Nordwand Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $785,273,000. Savant Capital LLC increased its holdings in shares of Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after acquiring an additional 3,588,251 shares during the last quarter. Edmp Inc. raised its stake in Johnson & Johnson by 17,222.9% in the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock valued at $18,247,000 after acquiring an additional 3,204,658 shares during the period. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the last quarter. Finally, GQG Partners LLC increased its holdings in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Up 0.4 %

NYSE JNJ opened at $161.65 on Thursday. The business has a fifty day moving average price of $158.80 and a two-hundred day moving average price of $166.87. The stock has a market capitalization of $420.08 billion, a PE ratio of 33.82, a PEG ratio of 2.77 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.67 earnings per share. Equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.94%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.

Insiders Place Their Bets

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. StockNews.com began coverage on Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Credit Suisse Group boosted their price target on Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Raymond James dropped their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.